Compass Pathways plc downgraded to Hold after mixed trial results. Explore upcoming catalysts in depression treatment and ...

A single dose of a synthetic psilocybin was found to improve symptoms in patients with treatment-resistant depression.

Compass Pathways took a 50% on June 23 hit after a lukewarm trial, but long-term bulls see upside in psychedelics.

Compass Pathways has announced that its investigational psilocybin therapy, COMP360, met the primary endpoint in its Phase 3 ...

Compass Pathways’ stock has crashed by nearly 50% despite the company announcing its Phase III trial of psilocybin had met ...

A second phase 3 trial, COMP006 (ClinicalTrials.gov Identifier: NCT05711940), is currently evaluating 2 administrations of COMP360 psilocybin in TRD patients, with 26-week data expected in the ...

An Iowa lawmaker who had pushed for the passage Gov. Kim Reynolds’ decision to veto a bill pertaining to the psychoactive ...

The UK-based firm earlier announced that it had met the primary endpoint in the ongoing 258-patient Phase III COMP005 trial, ...

Stifel said the plunge in Compass Pathways shares was “significantly overdone” after data showed that the company’s COMP360 ...

The company announced Monday that its COMP360 oral psilocybin treatment met the primary endpoint in the Phase 3 COMP005 trial for treatment-resistant depression (TRD), ...

In its third-quarter results update, Compass also caused jitters amongst its investors as it revealed that it will shift the data readout for phase 3 trials of the psilocybin-based COMP360 therapy ...